You are here

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Los Angeles, California, 90073 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Peptic Ulcer Hemorrhage
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must be men or nonpregnant women at least 18 years of age

- Patients who present with a gastric or duodenal ulcer (major dimension of the ulcer
must be ≥ 5 mm and ≤ 20 mm) with endoscopic appearance of spurting, oozing, or
nonbleeding visible vessel (NBVV) Patients presenting with adherent protruding clot
are eligible if, after removal of the clot by irrigation, the underlying lesion is
classified as spurting, oozing or a NBVV. Patients with an actively bleeding ulcer or
a NBVV within a hiatal hernia are eligible if the ulcer is located below the Z-line)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat
pigmented spot; adherent clots not removed by irrigation

- Patients presenting with active bleeding and/or NBVV at 2 or more separate sites

- Patients with any severe concomitant diseases, eg, end-stage liver or renal disease,
or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases

NCT00037570
Pfizer
Completed
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Ulcerative Colitis
NCT01470612
All Genders
18+
Years
Multiple Sites
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
NCT02539368
All Genders
18+
Years
Multiple Sites
Ulcerative Colitis, Inflammatory Bowel Disease
NCT00038922
All Genders
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
A Randomized Study of the Effect of Intravenous Pantoprazole on Gastric pH After Successful Hemostasis in Patients With Bleeding Peptic Ulcer
This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ranitidine (the comparator) within 2 hours of successful hemostasis and administration will continue for 72 hours after hemostasis.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Primary Purpose: Prevention
Peptic Ulcer Hemorrhage
Drug: Pantoprazole
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
February 2002
February 2002   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must be men or nonpregnant women at least 18 years of age
  • Patients who present with a gastric or duodenal ulcer (major dimension of the ulcer must be ? 5 mm and ? 20 mm) with endoscopic appearance of spurting, oozing, or nonbleeding visible vessel (NBVV) Patients presenting with adherent protruding clot are eligible if, after removal of the clot by irrigation, the underlying lesion is classified as spurting, oozing or a NBVV. Patients with an actively bleeding ulcer or a NBVV within a hiatal hernia are eligible if the ulcer is located below the Z-line)

Exclusion Criteria:

  • Patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat pigmented spot; adherent clots not removed by irrigation
  • Patients presenting with active bleeding and/or NBVV at 2 or more separate sites
  • Patients with any severe concomitant diseases, eg, end-stage liver or renal disease, or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00037570
3001K2-201
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor, MD Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
February 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now